Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Monte Rosa Therapeutics, Inc. GLUE NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
66/100
5/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$31.75
+81.4%

Monte Rosa Therapeutics, Inc. (GLUE) is a Biotechnology company in the Healthcare sector, currently trading at $17.50. It has a SharesGrow Score of 66/100, indicating a above average investment profile with 5 out of 7 criteria passed.

Analyst consensus target is GLUE = $32 (+81.4% upside).

Valuation: GLUE trades at a trailing Price-to-Earnings (P/E) of -29.5 (S&P 500 average ~25).

Financials: revenue is $124M, +63.5%/yr average growth. Net income is $39M (loss), growing at +21.3%/yr. Net profit margin is -31.2% (negative). Gross margin is 93.2% (+3.9 pp trend).

Balance sheet: total debt is $39M against $233M equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 6.12 (strong liquidity). Debt-to-assets is 8.7%. Total assets: $449M.

Analyst outlook: 7 / 9 analysts rate GLUE as buy (78%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 70/100 (Pass), Future 85/100 (Pass), Income 10/100 (Fail).

$31.75
▲ 81.43% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Monte Rosa Therapeutics, Inc., the average price target is $31.75, with a high forecast of $37.00, and a low forecast of $22.00.
Highest Price Target
$37.00
Average Price Target
$31.75
Lowest Price Target
$22.00

GLUE SharesGrow Score Overview

78/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 70/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GLUE

✓
VALUE Pass
100/100
GLUE trades at a trailing Price-to-Earnings (P/E) of -29.5 (S&P 500 average ~25). Forward PEG -2.34 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.1. Analyst consensus target is $32, implying +82.9% from the current price $18. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
GLUE: +63.5%/yr revenue is, +21.3%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet GLUE: Debt-to-Equity (D/E) ratio 0.17 (conservative), Current ratio is 6.12 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
70/100
GLUE: Gross margin is 93.2% (+3.9 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 7 / 9 analysts rate GLUE as buy (78%). Analyst consensus target is $32 (+82.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
GLUE: Net profit margin is -31.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.5-25.77
Volume631.41K
Avg Volume (30D)1.13M
Market Cap$1.14B
Beta (1Y)1.64
Share Statistics
EPS (TTM)-0.46
Shares Outstanding$83.07M
IPO Date2021-06-24
Employees142
CEOMarkus Warmuth
Financial Highlights & Ratios
Revenue (TTM)$123.67M
Gross Profit$115.32M
EBITDA$-45.85M
Net Income$-38.63M
Operating Income$-54.21M
Total Cash$377.1M
Total Debt$39.19M
Net Debt$-90.69M
Total Assets$448.66M
Price / Earnings (P/E)-38
Price / Sales (P/S)9.22
Analyst Forecast
1Y Price Target$34.00
Target High$37.00
Target Low$22.00
Upside+94.3%
Rating ConsensusBuy
Analysts Covering9
Buy 78% Hold 22% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS61225M1027

Price Chart

Track all markets on TradingView
GLUE
Monte Rosa Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
3.50 52WK RANGE 25.77

People Also View

KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.30
+2.45%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 LYEL
LYEL
Lyell Immunopharma, Inc.
$23.37
-5.77%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message